Related Experiment Video
Updated: Jul 16, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Updated guidelines for chronic active Epstein-Barr virus disease
Jun-Ichi Kawada1, Yoshinori Ito2, Koichi Ohshima3
1Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan. kawadaj@med.nagoya-u.ac.jp.
Insights
Updated guidelines for diagnosing and treating Chronic Active Epstein-Barr Virus Disease (CAEBV) emphasize confirming high Epstein-Barr virus (EBV) DNA loads and EBV-infected cells. Hematopoietic stem cell transplantation (HSCT) remains the only cure.
Area of Science:
- Immunology
- Virology
- Hematology
Background:
- Chronic Active Epstein-Barr Virus Disease (CAEBV) involves systemic inflammation and clonal proliferation of EBV-infected T or NK cells.
- CAEBV is a life-threatening illness requiring timely diagnosis and intervention for better clinical outcomes.
- Previous diagnostic guidelines for CAEBV have been updated to incorporate new evidence on pathogenesis and treatment.
Purpose of the Study:
- To present updated guidelines for the diagnosis and treatment of CAEBV.
- To improve the clinical management of CAEBV based on recent scientific evidence.
- To provide clear diagnostic criteria and therapeutic recommendations for healthcare professionals.
Main Methods:
- Review and synthesis of accumulated evidence on CAEBV pathogenesis and treatment.
- Establishment of updated diagnostic criteria for CAEBV.
- Identification of recommended therapeutic interventions.
Main Results:
- Updated CAEBV diagnosis requires confirmation of high EBV genome copy number and EBV-infected T or NK cells.
- An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff.
- Hematopoietic stem cell transplantation (HSCT) is identified as the only curative treatment, with chemotherapy used for pre-HSCT disease control.
Conclusions:
- The updated guidelines provide a refined approach to CAEBV diagnosis, incorporating quantitative EBV DNA load measurements.
- Hematopoietic stem cell transplantation (HSCT) is the definitive treatment for CAEBV.
- Further research may lead to standardized treatment protocols beyond HSCT.
Abstract:
Chronic active Epstein-Barr virus disease (CAEBV), formerly named chronic active Epstein-Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein-Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Tonsillitis II: Management
Chronic Kidney Disease IV: Nursing Management

